Molecular targeted therapy of BRAF-mutant colorectal cancer

Over the past two decades, the molecular characterization of metastatic colorectal cancer (mCRC) has been revolutionized by the routine implementation of RAS and BRAF tests. As a result, it is now known that patients with mCRC harboring BRAF mutations experience a poor prognosis. Although it account...

Descripción completa

Detalles Bibliográficos
Autores principales: Ducreux, Michel, Chamseddine, Ali, Laurent-Puig, Pierre, Smolenschi, Cristina, Hollebecque, Antoine, Dartigues, Peggy, Samallin, Emmanuelle, Boige, Valérie, Malka, David, Gelli, Maximiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582307/
https://www.ncbi.nlm.nih.gov/pubmed/31244912
http://dx.doi.org/10.1177/1758835919856494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582307/
https://www.ncbi.nlm.nih.gov/pubmed/31244912
http://dx.doi.org/10.1177/1758835919856494

Ejemplares similares